Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.
Glioblastoma
DRUG: Temozolomide|DRUG: Disulfiram|DIETARY_SUPPLEMENT: Copper gluconate
Pharmacological effect of disulfiram in GBM patients, Degree of proteasome inhibition in peripheral white blood cells and rate of complete inhibition in GBM patients using descriptive statistics, 30 days
Local tumor control probabilities, The Kaplan-Meier product-limit method will be used., 2 years|Time to tumor progression, Modeled using the Cox proportional hazard models., 2 years
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.